TD Cowen analyst Gary Taylor lowered the firm’s price target on Elevance Health to $564 from $577 and keeps an Outperform rating on the shares. The analyst noted our last model was published before the 2024 MA Advance Notice and had not yet reflected any MA rate headwind but we are assuming materially lower MA rate growth and only slightly lower MA enrollment growth in both 2024-25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ELV:
- Elevance Health reports Medical enrollment of 48.1M members on March 31
- Elevance Health raises FY23 adjusted EPS view to greater than $32.70 per share
- Elevance Health reports Q1 adjusted EPS 9.46, consensus $9.26
- Elevance Health, Inc. (ELV) Q1 Earnings Cheat Sheet
- Final Medicare Advantage rates positive for managed care, says JPMorgan